Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906096 · ClinicalTrials.gov registry record · Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
A Phase 2 study of Primary Central Nervous System Lymphoma and Non-Hodgkin Lymphoma of Extranodal Site, sponsored by Lakshmi Nayak, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT04906096: Recruiting Phase 2 study of Primary Central Nervous System Lymphoma and Non-Hodgkin Lymphoma of Extranodal Site, sponsored by Lakshmi Nayak, MD.
NCT04906096 is a Phase 2 study of Primary Central Nervous System Lymphoma and Non-Hodgkin Lymphoma of Extranodal Site that is actively recruiting participants, run by Lakshmi Nayak, MD. The registered enrollment target is 25 participants, below the 51-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (51% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04906096, a Phase 2 study of Primary Central Nervous System Lymphoma and Non-Hodgkin Lymphoma of Extranodal Site, is actively recruiting participants, sponsored by Lakshmi Nayak, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Primary Outcome
The Objective Response (ORR) is defined as a complete, unconfirmed complete or partial response as determined by the investigator assessment using IPCG criteria
Conditions Studied
Interventions
- DRUG PAXALISIB
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
What NCT04906096 shows while recruiting
NCT04906096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 51-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (51% lower).
The record links to 2 conditions, with Primary Central Nervous System Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which PAXALISIB is the first listed.
NCT04906096 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04906096 about?
NCT04906096 is a clinical study titled "Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL". This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
What is the current status of trial NCT04906096?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-06-01. Estimated completion is 2027-12-01.
What conditions does trial NCT04906096 study?
This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site.
What interventions are being tested in trial NCT04906096?
The interventions under investigation include: PAXALISIB (DRUG).
Who is sponsoring clinical trial NCT04906096?
This trial is sponsored by Lakshmi Nayak, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906096 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04906096's enrollment target sits among peer trials
25 8th of 12 higher than 4 of 12 other Primary Central Nervous System Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Central Nervous System Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
RECRUITING · Phase 2
-
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
RECRUITING · Phase 2
-
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
COMPLETED · Phase 2
-
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI